Swedish Orphan Biovitrum AB (OSTO:SOBI)

kr 276.4 3 (1.1%) Market Cap: 93.94 Bil Enterprise Value: 112.63 Bil PE Ratio: 43.61 PB Ratio: 2.63 GF Score: 87/100

Q1 2024 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 25, 2024

kr280.8 (+5.41%)

Earnings
Q4 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 08, 2024

kr259.4 (-7.95%)

Earnings
Q3 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 30, 2023

kr230 (+3.05%)

Earnings
Swedish Orphan Biovitrum AB (publ) KOL Haemophilia Call (Virtual) Transcript
Sep 18, 2023
Swedish Orphan Biovitrum AB (publ) KOL Event Call Transcript
Jul 19, 2023
Q2 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 18, 2023

kr203.26 (+3.40%)

Earnings
Swedish Orphan Biovitrum AB (publ) to Acquire CTI Biopharma Corp Call Transcript
May 10, 2023
Q1 2023 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 27, 2023

kr241.66 (-3.44%)

Earnings
Q4 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 08, 2023

kr234.3 (+4.07%)

Earnings
Q3 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 27, 2022

kr195.71 (-2.84%)

Earnings
Q2 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 19, 2022

kr217.3 (+4.45%)

Earnings
Q1 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 28, 2022

kr198.01 (-3.98%)

Earnings
Q4 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 10, 2022

kr181.63 (-1.09%)

Earnings
Q2 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 21, 2021

kr161.04 (+4.98%)

Earnings
Q1 2021 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
May 04, 2021

kr133.39 (-6.02%)

Earnings
Q4 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 18, 2021

kr142.94 (-9.22%)

Earnings
Swedish Orphan Biovitrum AB (publ) Capital Markets Day Transcript
Dec 10, 2020
Q3 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 22, 2020

kr145.19 (-6.23%)

Earnings
Q2 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 16, 2020

kr186.21 (-8.26%)

Earnings
Q1 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 29, 2020

kr175.04 (-4.71%)

Earnings
Q4 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 13, 2020

kr184.83 (+2.22%)

Earnings
Q3 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Oct 31, 2019

kr146.05 (-7.61%)

Earnings
Swedish Orphan Biovitrum AB (publ) to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology Call Transcript
Sep 30, 2019
Q2 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 17, 2019

kr198.2 (+10.37%)

Earnings
Swedish Orphan Biovitrum AB (publ) Capital Markets Day Transcript
May 14, 2019
Q1 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Apr 25, 2019

kr174.46 (-9.22%)

Earnings
Q4 2018 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 20, 2019

kr189.12 (-4.58%)

Earnings

Q2 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript

Jul 16, 2020 / 11:00AM GMT

Release Date Price: kr186.21 (-8.26%)

Transcript

Operator

Ladies and gentlemen, welcome to the Sobi presentation of the Q2 results. (Operator Instructions)

I will now hand over to Guido Oelkers, CEO. Please go ahead.

Guido Oelkers;publ;CEO;President

Swedish Orphan Biovitrum AB

()-&

Yes. Good afternoon, everybody. It's really a pleasure to have you here at our Q2 webcast. And I think with this having said, I will be joined today by Henrik Stenqvist, our CFO; and Milan Zdravkovic, our Head of R&D. And I think forward-looking statement as per usual. And why don't we go right into the beef of the presentation.

Yes. So basically, this is a difficult environment, and I understand that we are one of the -- we are the first group of pharma companies presenting. And I think, therefore -- I think it may be worthwhile to understand what happened actually in this environment. And I just want to refer to U.S. data that I just -- we just got recently hold of. So basically, in the U.S., total prescription between end of May and beginning of June are down 6%

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.